Predictive Value of Preoperative Serum CCL2, CCL18, and VEGF for the Patients with Gastric Cancer Jianghong Wu1,2†, Xiaowen Liu1,2† and Yanong Wang1,2*
Total Page:16
File Type:pdf, Size:1020Kb
Wu et al. BMC Clinical Pathology 2013, 13:15 http://www.biomedcentral.com/1472-6890/13/15 RESEARCH ARTICLE Open Access Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer Jianghong Wu1,2†, Xiaowen Liu1,2† and Yanong Wang1,2* Abstract Background: To investigate the expression of chemokine ligand 2 (CCL2), chemokine ligand 18 (CCL18), and vascular endothelial growth factor (VEGF) in peripheral blood of patients with gastric cancer and their correlation with presence of malignancy and disease progression. Methods: Sixty patients with pathological proved gastric cancer were prospectively included into study. The levels of CCL2, CCL18, and VEGF in peripheral blood were examined by enzyme-linked immunosorbentassay (ELISA). Peripheral blood from 20 healthy people was examined as control. Results: The preoperative serum levels of CCL2, CCL18 and VEGF in gastric cancer patients were significantly higher than that of controls (P <0.001, P <0.001, and P <0.001, respectively). ROC curve analysis showed that with a cut-off value of ≥1272.8, the VEGF*CCL2 predicted the presence of gastric cancer with 83% sensitivity and 80% specificity. Preoperative serum CCL2 was significantly correlated to N stage (P =0.040); CCL18 associated with N stage (P =0.002), and TNM stage (P =0.002); VEGF correlated to T stage (P =0.000), N stage (P =0.015), and TNM stage (P =0.000). Conclusion: Preoperative serum levels of CCL2 and VEGF could play a crucial role in predicting the presence and progression of gastric cancer. Keywords: Gastric cancer, Diagnosis, Biological markers Background Chemokines were a kind of low-molecular weight cy- Although the incidence of gastric cancer has been sub- tokines, which were implicated in many biological pro- stantially declining for several decades, it was still the cesses, such as migration of leukocytes, angiogenesis, fourth most common cancer and the second most fre- and tumor growth. The CCL chemokines represented quent cause of cancer death [1,2]. The high death rate the largest family of chemokines. They could attract was related to the difficulty of detecting gastric cancer at monocytes, macrophages, T cells, B cells, eosinophils, an early stage. Some serum tumor markers such as AFP, dendritic cells, mast cells and natural killer cells [3]. CEA, CA19-9, CA72-4, and CA50 were currently the CCL2 was a 76-amino acid protein that was originally puri- best clinical markers for gastric cancer. However, they fied and cloned from human gliomas and myelomonocytic were no good diagnostic tumor makers in early stage cells in 1989 [4]. CCL2 was the first chemokine discovered gastric cancer. Therefore, it was important to develop in the C-C subfamily of chemokines and was produced by new markers for detecting gastric cancer. a variety of cells. Some studies have implicated that CCL2 was an active participant in the tumor microenvironment [5,6]. CCL18 was a newly defined member of C-C sub- * Correspondence: [email protected] group of chemokines. It played an important role in in- †Equal contributors flammation and generation of the immune response. 1Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University However, the involvement of CCL18 in cancer was not Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, People’s Republic of China clear. 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China © 2013 Wu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Wu et al. BMC Clinical Pathology 2013, 13:15 Page 2 of 5 http://www.biomedcentral.com/1472-6890/13/15 Vascular endothelial growth factor (VEGF) was firstly groups were performed with Student’spairedt-test and isolated from the culture supernatant and the ascites of non-parametric Wilcoxon’s signed-rank test. Linear corre- rodent tumors a potent vascular permeability factor [7]. lations were assessed by calculating Pearson’scorrelation It was thought to be one of the most important factors coefficient or the non-parametric Spearman’s rho. The ac- promoting vascularization [8]. It played a role in both cepted level of significance was P <0.05. Statistical analyses physical and malignant conditions [9]. Previous studies and graphics were performed with the SPSS 13.0 statistical reported that serum VEGF level was high in several can- package (SPSS, Inc., Chicago, IL). cers, such as breast cancer and colon cancer [10,11]. The aim of this study was to investigate the relation- Results ship between the preoperative serum levels of CCL2, Clinicopathological characteristics CCL18, and VEGF, and the clinicopathological factors in There were 14 males and 6 females (2.33:1) with a mean patients with gastric cancer. age of 56 years in normal persons. There were 41 males and 19 females (2.16:1) with a mean age of 55 years. Methods There was 7 (11.7%) early gastric cancers and 53 (88.3%) Study population advanced gastric cancers. According to histological type, From July 2005 to December 2005, 60 patients who well-differentiated tumors were observed in 1 (1.7%) pa- underwent curative gastrectomy at department of Gas- tients, moderately-differentiated in 18 (30.0%) patients, tric Cancer and Soft Tissue Sarcoma in Shanghai Cancer and poorly-differentiated tumors in remaining 41 Hospital were included into this study. All patients were (68.3%) patients. Lymph node metastasis was observed confirmed as gastric cancer by preoperative biopsy. No pa- in 40 patients, the metastasis rate was 66.7%. The distri- tients received neoadjuvant treatment or preoperative bution of pathological stage was as follows: 11 (18.3%) blood transfusion. Additionally, 20 normal persons were patients belonged to stage I, 9 (15.1%) II, 23 (38.3%) III, designated as the control. Staging was performed according 17 (28.3%) IV. to the American Joint Committee on Cancer (AJCC) TNM Staging Classification for Carcinoma of the Stomach (6th edition, 2002). Data were retrieved from patients’ operative Serum CCL12, CCL18, and VEGF values and pathological reports. The written informed consent The serum values of CCL2, CCL18, and VEGF in normal had been obtained from all the patients, and this study was persons were 15.95 ± 1.15 (pg/ml), 42.46 ± 13.97 (pg/ml), approved by the Ethical Committee of Shanghai Cancer and 59.02 ± 6.28 (pg/ml), respectively. The serum values of Center of Fudan University. CCL2, CCL18, and VEGF in gastric cancers were 25.05 ± 1.22 (pg/ml), 115.94 ± 22.56 (pg/ml), and 132.92 ± 10.50 Blood samples (pg/ml), respectively. The levels were significantly higher in Blood samples were obtained by peripheral venous patients than that of control groups (Table 1). puncture on the day before operation. After clotting and within an hour of collection, the blood samples were Presence of malignancy centrifuged at 3000 g for 5 min and serum aliquots were Serum VEGF and CCL2 levels were significant inde- stored at -80°C until analysis. pendent predictors for the presence of gastric cancer. The optimal predictive model (χ2 =41.470, df =3, N =80, ELISA Negelkerke R2 =0.599, P <0.001) predicted presence of The measurement of CCL2, CCL18, and VEGF was performed using Quantikine human CCL2, CCL18, and Table 1 Comparisons of serum CCL2, CCL18, and VEGF VEGF sandwich enzyme-linked immunosorbent assay levels between gastric cancer patients and control (ELISA) kits (Genzyme Corporation, USA) according to groups the manufacturer’s instructions. All assays were duplicated. N Mean (pg/ml) Std. deviation P CCL2 < 0.001 Statistical analysis Patients 60 25.05 1.22 Continuous variables and categorical variables were Controls 20 15.95 1.15 expressed as mean ± 1 standard deviation and percentages, CCL18 < 0.001 respectively. The Kolmogorov-Smirnov test was used to Patients 60 115.94 22.56 assess whether the continuous variables conformed to a Controls 20 42.46 13.97 Gaussian pattern. Comparisons of continuous variables VEGF < 0.001 between independent groups were performed with Stu- Patients 60 132.92 10.50 dent’s unpaired t-test or Mann–Whitney non-parametric Controls 20 59.02 6.28 test. Comparisons of continuous variables between related Wu et al. BMC Clinical Pathology 2013, 13:15 Page 3 of 5 http://www.biomedcentral.com/1472-6890/13/15 malignancy with 93.3% sensitivity and 60.0% specificity. With a serum VEGF levels cut-off values ≥ 68.2 pg/ml, the sensitivity and specificity of VEGF to distinguish patients from controls were 83% and 60%, respect- ively. In contrast, with a serum CCL2 levels cut-off values ≥ 16.6 pg/ml, the sensitivity and specificity of CCL2 to distinguish patients from controls were 78% and 60%, respectively. With a cut-off value of ≥1272.8, the VEGF*CCL2 pre- dicted the presence of gastric cancer with 83% sensitivity and 80% specificity (Table 2). The concentrations prod- uct yielded the largest area under the ROC curve (0.895, P <0.001) (Figure 1). Correlation of preoperative serum markers and clinicopathological features Preoperative serum CCL2 was significantly correlated to age (r =0.433, P =0.001) and N stage (r = -0.266, P =0.040). Preoperative serum CCL18 was significantly P Figure 1 Combined ROC curve of serum CCL2 (area under the associated with histology type (r = -0.296, =0.022), N P P P curve 0.79, < 0.001), VEGF (area under the curve 0.83, <0.001) stage (r = -0.384, =0.002), and TNM stage (r = -0.386, and CCL2*VEGF cut-off values for the presence of gastric cancer.